Robert G. Finizio
Board Member
ZyVersa Therapeutics, Inc. (ZVSA)Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Robert G. Finizio
Robert G. Finizio is recorded as Board Member at ZyVersa Therapeutics, Inc. (ZVSA). ZyVersa Therapeutics, Inc. reported in an 8-K filed December 3, 2025 that Robert G. Finizio resigned as independent director, Chairman of the Compensation Committee, and member of the Audit Committee, effective December 2, 2025. ZyVersa Therapeutics, Inc. reported in an 8-K filed June 12, 2025 that Robert G. Finizio was appointed Class III director, effective June 11, 2025.
“On December 2, 2025, Robert G. Finizio notified the Board of Directors (the "Board") of ZyVersa Therapeutics, Inc. (the "Company") of his intention to resign from his Board positions as an independent director, Chairman of the Compensation Committee, and member of the Audit Committee.”
“With respect to Proposal No. 1, stockholders elected the Class III director nominees (Stephen C. Glover and Robert G. Finizio), each to hold office for a term of three years and until a successor is duly elected and qualified.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
2025-06-11–present
-
2025-06-11–2025-12-02
-
Start not stated–2025-12-02
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at ZyVersa Therapeutics, Inc.
Other people whose current roles at this company are on record from its filings.
- Stephen C. Glover CEO, Board Member
- Peter Wolfe CFO
- Daniel J. O'Connor Board Member
- Gregory Freitag Board Member
- James Sapirstein Board Member
- Katrin Rupalla Board Member
- Min Chul Park, Ph.D. Board Member
- Min-Chul Park Board Member
- Rob G. Finizio Board Member
- Robert Finizio Board Member
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.